You are here: Industry Insights > Asthma

News List

Big Pharma's antibody drugs for asthma show benefits but cost 50% too much: ICER fiercepharma
September 27, 2018
New antibody-based treatments are better than traditional drugs for moderate to severe asthma, but they still cost too much, a U.S. drug cost watchdog says. More than 50% too much, in fact.
Paracetamol use in infancy may increase the risk of asthma europeanpharmaceuticalreview
September 18, 2018
A study has found that paracetamol use in infancy, as well as genetic factors, may increase the likelihood of developing asthma…
Severe asthma patients to get ‘life-changing’ procedure on NHS pharmatimes
September 14, 2018
A novel treatment for patients with asthma uncontrolled by medicines that involves reducing muscle mass in the lungs has been approved...
MS Society launches petition against NICE’s rejection of Ocrevus The MS Society has launched a petition imploring t
September 14, 2018
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche...
UK first EU nation to launch flutiform k-haler for asthma pharmatimes
September 14, 2018
Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma.
AstraZeneca, Amgen’s tezepelumab wins ‘breakthrough’ status pharmatimes
September 13, 2018
AstraZeneca and Amgen’s tezepelumab has won breakthrough therapy status in the US for its potential to treat severe asthma without an eosinophilic phenotype.
Tezepelumab granted Breakthrough Therapy Designation by US FDA worldpharmanews
September 10, 2018
AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma
School Prep Includes Planning Allergy, Asthma Management drugs
August 08, 2018
Allergies and asthma can make the start of the new school year a challenge for kids who aren't prepared to deal with flare-ups, an allergist warns.
EU reviews for Sanofi’s Dupixent, cemiplimab pharmatimes
July 19, 2018
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Study demonstrates new treatment for severe asthma worldpharmanews
June 05, 2018
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page